1. Bendix, G., & Bjelle, A. A. (1996). 10 year follow up of parenteral gold therapy in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 55(3), 169–176.
2. Bernstein, I. L., Bernstein, D. I., Dubb, J. W., Faiferman, I., & Wallin, B. (1996). A placebo-controlled multicenter study of auranofin in the treatment of patients with corticosteroid-dependent asthma. Auranofin Multicenter Drug Trial. Journal of Allergy & Clinical Immunology, 98(2), 317–324.
3. Choy, E. H., Gambling, L., Best, S. L., Jenkins, R. E., Kondeatis, E., Vaughan, R., et al. (1997). Nickel contamination of gold salts: Link with gold-induced skin rash. British Journal of Rheumatology, 36(10), 1054–1058.
4. Elder, R. C., Zhao, Z., Zhang, Y., Dorsey, J. G., Hess, E. V., & Tepperman, K. (1993). Dicyanogold (I) is a common human metabolite of different gold drugs. Journal of Rheumatology, 20(2), 268–272.
5. Evans, D.J., Cullinan, P., & Geddes D.M. (2001). Gold as an oral corticosteroid sparing agent in stable asthma. Cochrane Database of Systematic Reviews, (2):CD002985.